deltatrials

Geographic atrophy Trials in Cleveland, United States

Conditions / Geographic atrophy / Cleveland, United States

Clinical trials for Geographic atrophy investigate a range of treatment strategies and patient populations.

21 total trials for this combination

Showing top 10 of 21 trials

Trials

NCT ID Title Status Phase
NCT06510816 A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA) ACTIVE_NOT_RECRUITING PHASE3
NCT02686658 Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration COMPLETED PHASE2/PHASE3
NCT04465955 A Study of NGM621 in Participants With Geographic Atrophy COMPLETED PHASE2
NCT02247479 A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration TERMINATED PHASE3
NCT06635148 A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) RECRUITING PHASE2
NCT03972709 A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) TERMINATED PHASE2
NCT03815825 GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) COMPLETED PHASE2
NCT03525600 Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration COMPLETED PHASE3
NCT05811351 A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) COMPLETED PHASE2
NCT02745119 Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) TERMINATED PHASE3

Related Pages